Short-term efficacy and safety of nondamaging retinal laser therapy for retinitis pigmentosa-associated cystoid macular edema.

BACKGROUND/AIM: To evaluate the short-term efficacy and safety of nondamaging retinal laser therapy (NRT) for retinitis pigmentosa-associated cystoid macular edema (RP-CME) and analyze anatomical and functional outcomes.

MATERIALS AND METHODS

A retrospective case series of 40 eyes from 30 patients with RP-CME was conducted. The patients underwent NRT using a PASCAL laser system with endpoint management (EpM) software. Central macular thickness (CMT) and best-corrected visual acuity (BCVA) were assessed at baseline and 2 months posttreatment. Long-term follow-up data, including recurrence rates were also reviewed.

RESULTS

At the 2-month follow-up, NRT significantly reduced mean CMT by 79.7 μm (p < 0.001) and improved BCVA by 0.10 LogMAR (p < 0.001). Complete resolution of CME was observed in 30% of the eyes, while 52.5% experienced recurrence within 6 months. Unilateral cases exhibited greater CMT reductions than bilateral cases (p < 0.05). No retinal damage from the laser was observed. The long-term sustainability of these effects remains unclear, and repeated treatments have not yet been assessed.

CONCLUSION

NRT is a safe and effective short-term treatment for RP-CME, achieving significant anatomical and functional improvements without evidence of retinal damage. However, the high recurrence rate and absence of long-term data warrant further investigation. Future studies should explore repeated treatments, genetic subtypes, and correlations with the ellipsoid zone integrity.